Exhibit  99.1



FOR  IMMEDIATE  RELEASE

For  Further  Information:

Steven  Sobieski,  CFO
Phone:  908-947-1100
E-mail:  ssobieski@lifecell.com



                   LIFECELL SECURES $4 MILLION CREDIT FACILITY
                            FROM SILICON VALLEY BANK


BRANCHBURG,  N.J.,  JANUARY 30, 2003 - LifeCell Corporation (NASDAQ: LIFC) today
                                                                     ----
announced  that  it  has  secured  a  $4 million credit facility through Silicon
Valley Bank, a leading banking firm serving emerging and mature companies in the
high-tech  and  life  sciences industries.  The credit facility consists of a $2
million  revolving  line of credit and an equipment line for up to an additional
$2  million.  The  credit  facility will be used to replace $900,000 of existing
term  debt  and will provide access to additional working capital to support the
Company's  growth.

"We  are  pleased  with  the  confidence  Silicon  Valley  Bank has shown in our
business  model  by  extending this credit facility," said Steven Sobieski, Vice
President  and  Chief  Financial  Officer  of  LifeCell.  "Silicon  Valley  Bank
provides  us  a broad range of financial product offerings and the experience to
meet  the  needs  of  our  growing  company,"  Mr.  Sobieski  added.


ABOUT  LIFECELL
---------------

LifeCell  is  a  leader in developing and marketing biologically based solutions
for  the  repair  and  replacement  of  damaged or inadequate tissue in numerous
different  clinical  applications.  The  Company's  proprietary  tissue  matrix
technology  removes cells from allograft tissue and preserves the tissue without
damaging  the  essential  biochemical  and  structural  components necessary for
normal  tissue  regeneration.  LifeCell currently markets four proprietary human
tissue  based  products:  AlloDerm(R)  for  plastic  reconstructive  and  burn
procedures  through LifeCell's direct sales force and for periodontal procedures
through BioHorizons, Inc.; Cymetra(R), a version of AlloDerm in particulate form
for the correction of soft tissue defects, through LifeCell's direct sales force
and  a  co-promotion  agreement  with  OMP,  Inc.;  Repliform(TM),  a version of
AlloDerm  for  urology  and  gynecology  procedures,  through  a  marketing  and
distribution agreement with Boston Scientific Corporation; and Graft Jacket(TM),
an  acellular periostium replacement graft through a distribution agreement with
Wright  Medical  Group,  Inc.  The Company is also the exclusive marketing agent
for the SmartPReP(TM) Platelet Concentration System in the United States to ENT,
plastic  reconstructive  and  general  surgeons  in  hospitals.  The  Company's
development  programs include the application of its tissue matrix technology to
vascular,  nerve and orthopedic tissue repair; investigation of human tissues as
carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of
platelets  and  technologies  to  enhance  the  storage  of  red blood cells for
transfusion.  Visit  our  website  at  www.lifecell.com.
                                       ----------------


                                      -32-

                                    - more -

                                                                          page 2


ABOUT  SILICON  VALLEY  BANK
----------------------------

Silicon  Valley  Bank  serves  emerging  growth  and  mature  companies  in  the
technology  and  life  sciences  markets,  as well as other targeted industries.
Through  its  focus on specialized markets and extensive knowledge of the people
and  business  issues  driving  them,  Silicon  Valley  Bank provides a level of
service  and  partnership that measurably impacts its clients' success.  Founded
in  1983  and  headquartered  in Santa Clara, California, the Bank services more
than  9,500  clients  across  the  country  through  27  regional  offices. More
information  on  the  Bank  can  be  found  at  www.svb.com.
                                                -----------

This  release  contains  forward-looking  statements  made  pursuant to the safe
harbor  provisions of the Private Securities Litigation Reform Act of 1995, such
as the Company's ability to develop and market new products and continue to grow
its  business  in  2003  and  beyond.  Forward-looking  statements  represent
management's  judgment  regarding  future  events.  Although management believes
that  the expectations reflected in such statements are reasonable, they give no
assurance  that  such  expectations  will  prove to be correct and you should be
aware  that  actual  results could differ materially from those contained in the
forward-looking  statements  due  to a number of factors.  These factors include
the  risks  detailed  in  the  Company's Annual Report on Form 10-K for the year
ended December 31, 2001 and other reports filed with the Securities and Exchange
Commission.



                                       ###



                                      -33-